Analytical Data
-
Gene name
CD69
- Application
-
Alternative Names
CD69; CLEC2-C; AIM; p60; EA1; MLR-3; Early T-Cell Activation Antigen p60; Early activation antigen CD69; Activation inducer molecule; Leukocyte surface antigen Leu-23
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
Q5M851
-
Expression Region
Cys43~Glu187
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD69 is an early activation marker expressed on various immune cells, including T cells, B cells, and natural killer (NK) cells. Research on CD69 has gained significance due to its role in modulating immune responses during infections, autoimmune diseases, and cancer. It is a type II glycoprotein and functions primarily as a signaling molecule that influences cell proliferation, survival, and migration. The interest in recombinant CD69 protein arises from its potential applications in immunotherapy and vaccine development. By generating recombinant CD69, researchers aim to better understand its structural and functional properties, providing insights into its role in immune regulation. Additionally, recombinant CD69 can be used to investigate its interactions with other immune receptors and ligands, potentially unveiling novel therapeutic targets. Studies have demonstrated that CD69 can enhance the cytotoxic activity of NK cells and promote the formation of memory T cells, making it a crucial component in the context of immune enhancement strategies. As research progresses, understanding the molecular mechanisms underlying CD69 function and its impact on immune modulation could lead to innovative approaches in treating various diseases, ultimately contributing to improved therapeutic outcomes. Therefore, the study of recombinant CD69 represents a vital area of investigation in immunology, with broad implications for enhancing immune responses and developing new therapies.
